Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Compass Group's (CMPGY) stock surged 152% in five years, driven by strategic acquisitions and strong fundamentals. See why I ...

Stellantis has teased the upcoming second generation Compass ahead of its global debut ... the body is being dropped onto the chassis on the assembly line, signifying assembly of the pre ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

The Jeep Compass doesn't get a ton of respect. It's an entry-level vehicle that is filling the gap between the loved Renegade, and the capable Cherokee. It's based on older FCA tech, but it's ...

You can cut through some of the election noise with Vote Compass, which returns for the 2025 federal election. You put in your postcode to narrow down to your electorate, answer 30 questions ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

“But the bottom line: It’s tricky to see such a broad mixture of stocks winning here, from ones that can run in a recession to ones that can rally hard in a robust economy. What it tells me is ...